First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany

H Salwender; K Wendelin; F Oduncu; C Kimmich; R Naumann; M Kull; H Goldschmidt; M Ehmer; F Brand; C Kiewitz; C Khandanpour

First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany

H Salwender, K Wendelin, F Oduncu, C Kimmich, R Naumann, M Kull, H Goldschmidt, M Ehmer, F Brand, C Kiewitz, C Khandanpour

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	315-316
Number of pages	2
Journal	Oncology Research and Treatment
Volume	46
Publication status	Published - 2023
Externally published	Yes

Cite this

Salwender, H., Wendelin, K., Oduncu, F., Kimmich, C., Naumann, R., Kull, M., Goldschmidt, H., Ehmer, M., Brand, F., Kiewitz, C., & Khandanpour, C. (2023). First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany. Oncology Research and Treatment, 46, 315-316.

@article{0062f7685326460680049f90b3882399,

title = "First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany",

author = "H Salwender and K Wendelin and F Oduncu and C Kimmich and R Naumann and M Kull and H Goldschmidt and M Ehmer and F Brand and C Kiewitz and C Khandanpour",

note = "Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0",

year = "2023",

language = "English",

volume = "46",

pages = "315--316",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "Karger ",

}

Salwender, H, Wendelin, K, Oduncu, F, Kimmich, C, Naumann, R, Kull, M, Goldschmidt, H, Ehmer, M, Brand, F, Kiewitz, C & Khandanpour, C 2023, 'First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany', Oncology Research and Treatment, vol. 46, pp. 315-316.

TY - JOUR

T1 - First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany

AU - Salwender, H

AU - Wendelin, K

AU - Oduncu, F

AU - Kimmich, C

AU - Naumann, R

AU - Kull, M

AU - Goldschmidt, H

AU - Ehmer, M

AU - Brand, F

AU - Kiewitz, C

AU - Khandanpour, C

N1 - Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0

PY - 2023

Y1 - 2023

M3 - Abstract (Journal)

SN - 2296-5270

VL - 46

SP - 315

EP - 316

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

ER -